Dr. Reddy's Laboratories announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the U.S. Food and Drug Administration (USFDA).

The Bloxiverz brand and generic had U.S. sales of approximately USD 111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health.

Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials.

Shares of the company gained Rs 17.3, or 0.67%, to trade at Rs 2,582.60. The total volume of shares traded was 22,888 at the BSE (10.31 a.m., Friday).